Hyelyoung Jang is an analytical scientist at Samsung Biologics. She successfully completed a number of projects on the formulation development. She also played a key role in the launch of SBL’s rapid developability assessment platform, DEVELOPICK. Hyelyoung earned a bachelor’s and a Master of Engineering (MEng) degree in Biomedical Engineering from Imperial College London. She conducted her thesis research on the engineering of recombinant fusion proteins to develop novel therapeutics for an effective treatment of cytokine release syndrome.